← Back to Screener
Immunocore Holdings plc American Depositary Shares (IMCR)
Price$29.13
Value ScoreD
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-41.87%
Price vs S&P 500 (4W)-2.38%
VGM Score50.64
Market Capitalization$1.47B
All Metrics
P/CF (Annual)62.82x
Book Value / Share (Quarterly)$7.74
P/TBV (Annual)9.82x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)40.67%
Cash Flow / Share (Quarterly)$-0.50
Price vs S&P 500 (YTD)-27.70%
Gross Margin (TTM)98.86%
Net Profit Margin (TTM)-6.68%
EPS (TTM)$-0.56
10-Day Avg Trading Volume0.43M
EPS Excl Extra (TTM)$-0.56
Revenue Growth (5Y)67.77%
EPS (Annual)$-0.71
ROI (Annual)-4.59%
Gross Margin (Annual)98.73%
Net Profit Margin (5Y Avg)-114.48%
Cash / Share (Quarterly)$16.62
Revenue Growth QoQ (YoY)13.63%
ROA (Last FY)-3.33%
Revenue Growth TTM (YoY)23.75%
EBITD / Share (TTM)$-0.61
ROE (5Y Avg)-25.99%
Operating Margin (TTM)-8.35%
Cash Flow / Share (Annual)$-0.30
P/B Ratio3.73x
P/B Ratio (Quarterly)3.88x
Net Income / Employee (Annual)$-67,800
EV / Revenue (TTM)3.41x
Net Interest Coverage (TTM)-176.01x
ROA (TTM)-2.55%
EPS Growth QoQ (YoY)153.36%
EPS Incl Extra (Annual)$-0.71
Current Ratio (Annual)4.04x
Quick Ratio (Quarterly)3.86x
3-Month Avg Trading Volume0.42M
52-Week Price Return-17.55%
EV / Free Cash Flow (Annual)73.32x
Revenue / Employee (TTM)$787,800
Tangible BV / Share (Quarterly)$169.97
P/S Ratio (Annual)3.67x
Asset Turnover (Annual)0.37x
52-Week High$40.71
Operating Margin (5Y Avg)-119.14%
EPS Excl Extra (Annual)$-0.71
CapEx CAGR (5Y)7.17%
26-Week Price Return-25.94%
Quick Ratio (Annual)3.94x
13-Week Price Return-9.83%
Total Debt / Equity (Annual)1.03x
Current Ratio (Quarterly)4.18x
Enterprise Value$1.41B
Revenue / Share Growth (5Y)62.02%
Asset Turnover (TTM)0.38x
Revenue / Employee (Annual)$763,400
Inventory Turnover (Annual)0.83x
Pretax Margin (Annual)-4.77%
Cash / Share (Annual)$17.05
3-Month Return Std Dev35.86%
Net Income / Employee (TTM)$-52,600
ROE (Last FY)-9.32%
Net Interest Coverage (Annual)-25.02x
EPS Basic Excl Extra (Annual)$-0.71
P/FCF (TTM)31.93x
Receivables Turnover (TTM)5.73x
EV / Free Cash Flow (TTM)519.48x
Total Debt / Equity (Quarterly)1.00x
EPS Incl Extra (TTM)$-0.56
Receivables Turnover (Annual)5.84x
ROI (TTM)-3.52%
P/S Ratio (TTM)3.56x
Pretax Margin (5Y Avg)-121.73%
Revenue / Share (Annual)$7.95
Tangible BV / Share (Annual)$5.79
Forward P/E239.35x
Price vs S&P 500 (52W)-45.76%
Year-to-Date Return-16.77%
5-Day Price Return0.21%
EPS Normalized (Annual)$-0.71
ROA (5Y Avg)-14.14%
Net Profit Margin (Annual)-8.88%
Month-to-Date Return3.51%
Cash Flow / Share (TTM)$-1.24
EBITD / Share (Annual)$-0.84
Operating Margin (Annual)-11.34%
LT Debt / Equity (Annual)1.03x
P/CF (TTM)204.86x
ROI (5Y Avg)-18.48%
LT Debt / Equity (Quarterly)1.00x
EPS Basic Excl Extra (TTM)$-0.56
P/TBV (Quarterly)6.45x
P/B Ratio (Annual)4.52x
Inventory Turnover (TTM)0.62x
Pretax Margin (TTM)-2.89%
Book Value / Share (Annual)$7.52
Price vs S&P 500 (13W)-19.58%
Beta0.75x
P/FCF (Annual)70.31x
Revenue / Share (TTM)$7.80
ROE (TTM)-7.07%
52-Week Low$27.55
vGradeD
gGradeB
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.25est. -0.26
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.17
4.17
4.09
4.09
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IMCRImmunocore Holdings plc American Depositary Shares | D | B | D | $29.13 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Immunocore is a commercial-stage biotechnology company that markets KIMMTRAK for unresectable and metastatic uveal melanoma. The company leverages its proprietary ImmTAX platform to develop a pipeline of candidates across oncology, infectious disease, and autoimmune disorders, including Brenetafusp and other clinical and pre-clinical programs.